339 related articles for article (PubMed ID: 28830923)
41. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
42. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.
Kato S; Schwaederle M; Daniels GA; Piccioni D; Kesari S; Bazhenova L; Shimabukuro K; Parker BA; Fanta P; Kurzrock R
Cell Cycle; 2015; 14(8):1252-9. PubMed ID: 25695927
[TBL] [Abstract][Full Text] [Related]
43. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
Witkiewicz AK; Borja NA; Franco J; Brody JR; Yeo CJ; Mansour J; Choti MA; McCue P; Knudsen ES
Oncotarget; 2015 Jun; 6(18):15788-801. PubMed ID: 26158861
[TBL] [Abstract][Full Text] [Related]
44. A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.
Jones R; Ruas M; Gregory F; Moulin S; Delia D; Manoukian S; Rowe J; Brookes S; Peters G
Cancer Res; 2007 Oct; 67(19):9134-41. PubMed ID: 17909018
[TBL] [Abstract][Full Text] [Related]
45. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
Kalu NN; Johnson FM
Expert Opin Investig Drugs; 2017 Feb; 26(2):207-217. PubMed ID: 28042706
[TBL] [Abstract][Full Text] [Related]
46. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
[TBL] [Abstract][Full Text] [Related]
47. Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
Niwa Y; Asano M; Nakagawa T; France D; Semba T; Funahashi Y
Anticancer Res; 2020 Dec; 40(12):6699-6712. PubMed ID: 33288563
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
49. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Herrera-Abreu MT; Palafox M; Asghar U; Rivas MA; Cutts RJ; Garcia-Murillas I; Pearson A; Guzman M; Rodriguez O; Grueso J; Bellet M; Cortés J; Elliott R; Pancholi S; Baselga J; Dowsett M; Martin LA; Turner NC; Serra V
Cancer Res; 2016 Apr; 76(8):2301-13. PubMed ID: 27020857
[TBL] [Abstract][Full Text] [Related]
50. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
[TBL] [Abstract][Full Text] [Related]
51. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
[TBL] [Abstract][Full Text] [Related]
52. Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in
Shi R; Li M; Raghavan V; Tam S; Cabanero M; Pham NA; Shepherd FA; Moghal N; Tsao MS
Clin Cancer Res; 2018 Dec; 24(23):5990-6000. PubMed ID: 30093452
[TBL] [Abstract][Full Text] [Related]
53. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
[TBL] [Abstract][Full Text] [Related]
54. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component.
Xu G; Li JY
J Neurooncol; 2018 Feb; 136(3):445-452. PubMed ID: 29150788
[TBL] [Abstract][Full Text] [Related]
55. Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.
Yan J; Wu X; Yu J; Yu H; Xu T; Brown KM; Bai X; Dai J; Ma M; Tang H; Si L; Chi Z; Sheng X; Cui C; Kong Y; Guo J
Eur J Cancer; 2018 Jan; 89():90-101. PubMed ID: 29245078
[TBL] [Abstract][Full Text] [Related]
56. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
Holland EA; Schmid H; Kefford RF; Mann GJ
Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
[TBL] [Abstract][Full Text] [Related]
57. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.
Hayes TK; Luo F; Cohen O; Goodale AB; Lee Y; Pantel S; Bagul M; Piccioni F; Root DE; Garraway LA; Meyerson M; Johannessen CM
Cancer Res; 2019 May; 79(9):2352-2366. PubMed ID: 30819666
[TBL] [Abstract][Full Text] [Related]
58. C-terminal domain of p16(INK4a) is adequate in inducing cell cycle arrest, growth inhibition and CDK4/6 interaction similar to the full length protein in HT-1080 fibrosarcoma cells.
Fahham N; Sardari S; Ostad SN; Vaziri B; Ghahremani MH
J Cell Biochem; 2010 Dec; 111(6):1598-606. PubMed ID: 21053367
[TBL] [Abstract][Full Text] [Related]
59. CDK4/6 Inhibitors in Melanoma: A Comprehensive Review.
Garutti M; Targato G; Buriolla S; Palmero L; Minisini AM; Puglisi F
Cells; 2021 May; 10(6):. PubMed ID: 34071228
[TBL] [Abstract][Full Text] [Related]
60. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
